Curis, Inc. (CRIS) vs Lakewood-Amedex Biotherapeutics, Inc. (LABT)

A side-by-side comparison of Curis, Inc. and Lakewood-Amedex Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Curis, Inc. logo
CRIS
Curis, Inc.
$1M
$0.75HealthcareDelayed quote: Oct 6, 2026, 3:33 PM EDT
Lakewood-Amedex Biotherapeutics, Inc. logo
LABT
Lakewood-Amedex Biotherapeutics, Inc.
$2M
$0.86HealthcareDelayed quote: Oct 6, 2026, 3:26 PM EDT

Total return — CRIS vs LABT

growth of $100 · dividends reinvested · last 1y
CRIS -93.6% (-93.6%/yr)LABT -99.0% (-99.0%/yr)CRIS compounded faster over this window
Log scale — wide-divergence pair
0110100Start $100$6$1
CRIS LABT

CRIS vs LABT: by the numbers

  • •LABT is the larger company ($2M vs $1M market cap).
  • •Both run net losses; LABT's is the smaller (0.00% vs -490.33% net margin).

Metrics side by side

Valuation

MetricCRISLABT
P/S ratio0.34N/A
P/B ratio0.310.35

Profitability

MetricCRISLABT
Gross margin99.28%0.00%
Operating margin-348.43%0.00%
Net margin-490.33%0.00%
ROE-450.54%-169.64%
ROIC-567.17%-163.98%

Growth (annualized)

MetricCRISLABT
Revenue CAGR (5Y)-15.88%N/A
Total return CAGR (5Y)-81.06%N/A

Go deeper

Full CRIS analysisFull LABT analysisInteractive comparison tool

Dig into the metrics

Curis ROELakewood-Amedex Biotherapeutics ROECuris operating marginLakewood-Amedex Biotherapeutics operating marginCuris revenue growthLakewood-Amedex Biotherapeutics revenue growthCuris free cash flowLakewood-Amedex Biotherapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.